Zobrazeno 1 - 10
of 19
pro vyhledávání: '"William Copalu"'
Autor:
Munjal Patel, Francesco Bellanti, Naveen M. Daryani, Nadia Noormohamed, David W. Hilbert, Katherine Young, Pooja Kulkarni, William Copalu, Ferdous Gheyas, Matthew L. Rizk
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 2, Pp 396-408 (2022)
Abstract In the phase III RESTORE‐IMI 2 study (ClinicalTrials.gov: NCT02493764), the combination antibacterial agent imipenem/cilastatin/relebactam (IMI/REL) demonstrated noninferiority to piperacillin/tazobactam for the end points of all‐cause m
Externí odkaz:
https://doaj.org/article/2fe004e1c4e6439c87c133441ff0e7a8
Autor:
Pratik Bhagunde, Parul Patel, Mallika Lala, Kenny Watson, William Copalu, Ming Xu, Pooja Kulkarni, Katherine Young, Matthew L. Rizk
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 10, Pp 748-758 (2019)
Relebactam is a small‐molecule β‐lactamase inhibitor developed as a fixed‐dose combination with imipenem/cilastatin. The pharmacokinetics of relebactam and imipenem across 10 clinical studies were analyzed using data from adult healthy volunte
Externí odkaz:
https://doaj.org/article/16930bafa9fd42f6b4ceaac5cf976f1b
Autor:
Katherine Young, Ferdous Gheyas, Francesco Bellanti, Pooja Kulkarni, David W. Hilbert, Munjal Patel, William Copalu, Matthew L. Rizk, Naveen M. Daryani, Nadia Z. Noormohamed
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 2, Pp 396-408 (2022)
In the phase III RESTORE‐IMI 2 study (ClinicalTrials.gov: NCT02493764), the combination antibacterial agent imipenem/cilastatin/relebactam (IMI/REL) demonstrated noninferiority to piperacillin/tazobactam for the end points of all‐cause mortality
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::568dd7388abaccc3b763d679304fd2a7
https://doi.org/10.1111/cts.13158
https://doi.org/10.1111/cts.13158
Autor:
Katherine Young, Pratik Bhagunde, Matthew L. Rizk, Mallika Lala, Kenny Watson, Ming Xu, Pooja Kulkarni, William Copalu, Parul Patel
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 10, Pp 748-758 (2019)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Relebactam is a small-molecule β-lactamase inhibitor developed as a fixed-dose combination with imipenem/cilastatin. The pharmacokinetics of relebactam and imipenem across 10 clinical studies were analyzed using data from adult healthy volunteers an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c749aed133b13b2a9aea9e58cf0414b5
https://doaj.org/article/16930bafa9fd42f6b4ceaac5cf976f1b
https://doaj.org/article/16930bafa9fd42f6b4ceaac5cf976f1b
Autor:
Petronella O. Witteveen, Larisa Reyderman, Jantien Wanders, Serena Marchetti, Kenneth Law, Fuping Peng, Jos H. Beijnen, Emile E. Voest, Alwin D. R. Huitema, Jan H.M. Schellens, William Copalu, Lot A. Devriese, Geoff Edwards
Publikováno v:
British Journal of Clinical Pharmacology. 75:507-521
Aim Eribulin mesylate is a non-taxane microtubule dynamics inhibitor that was recently approved for treatment of metastatic breast cancer. The aim of this study was to determine the effect of rifampicin, a CYP3A4 inducer, on the plasma pharmacokineti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e706dd9c322ac8ae6632dd938f8174c
https://doi.org/10.1111/j.1365-2125.2012.04381.x
https://doi.org/10.1111/j.1365-2125.2012.04381.x
Publikováno v:
Archives of Disease in Childhood. 97:1081-1085
BackgroundSodium phenylbutyrate (NaPB) is used as a treatment for urea cycle disorders (UCD). However, the available, licensed granule form has an extremely bad taste, which can compromise compliance and metabolic control.ObjectivesA new, taste-maske
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc7fc8e1dd263b6f7cf50d15289be9cc
https://doi.org/10.1136/archdischild-2012-302398
https://doi.org/10.1136/archdischild-2012-302398
Autor:
William Copalu, A. Mazur, Jantien Wanders, M Keesen, R. Morrison, D. S. Boss, Jos H. Beijnen, J P O'Brien, Jan H.M. Schellens, Hilary Glen, Thomas J. Evans, B Tait
Publikováno v:
British Journal of Cancer
Background: The objectives of this phase I study were to assess the safety and tolerability of E7080 in patients with advanced, refractory solid tumours; to determine the maximum tolerated dose (MTD) and pharmacokinetics profile of E7080; and to expl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::829756bf3d74dbdd2f3e8f13873b85b4
http://europepmc.org/articles/PMC3349182
http://europepmc.org/articles/PMC3349182
Autor:
Anthe S. Zandvliet, Alwin D. R. Huitema, William Copalu, Jos H. Beijnen, Jan H.M. Schellens, Mats O. Karlsson
Publikováno v:
Investigational New Drugs
Summary Background The phase I program of anticancer agents usually consists of multiple dose escalation studies to select a safe dose for various administration schedules. We hypothesized that pharmacokinetic and pharmacodynamic (PK–PD) modeling o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8c92abed6b82ae098b8d9e3838835f8
https://doi.org/10.1007/s10637-008-9216-2
https://doi.org/10.1007/s10637-008-9216-2
Publikováno v:
Drug Metabolism and Disposition. 34:1041-1046
The anticancer agent indisulam has a nonlinear pharmacokinetic profile, which may be partly related to saturable binding to blood constituents. To gain insight into the complex nonlinear behavior of indisulam, we investigated binding to plasma protei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ae702c7f848c75aa46e97ccd03501fb
https://doi.org/10.1124/dmd.105.008326
https://doi.org/10.1124/dmd.105.008326
Autor:
William Copalu, Lot A. Devriese, Larisa Reyderman, Jos H. Beijnen, Marja Mergui-Roelvink, Jantien Wanders, Serena Marchetti, A. Jenner, G. Edwards, F. Peng, Jan H.M. Schellens
Publikováno v:
Investigational new drugs. 31(2)
Purpose To study the influence of repeated oral administration of ketoconazole, a potent CYP3A4 inhibitor, on the plasma pharmacokinetics of eribulin mesylate administered by single-dose intravenous infusion. Eribulin mesylate is a non-taxane microtu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b3aeb4ce8b922ce1b4bc8e1b6b94cbf
https://pubmed.ncbi.nlm.nih.gov/22555773
https://pubmed.ncbi.nlm.nih.gov/22555773